The functionality and economic costs of outpatients with schizophrenia in Taiwan

Psychiatry Research

Volumn 158, Issue 3, 2008, Pages 306-315

  Lee, I Hui ^a,b   Chen, Po See ^a,b   Yang, Yen Kuang ^a,b   Liao, Yi Cheng ^c   Lee, Yih Dar ^a,d   Yeh, Tzung Lieh ^a,b   Yeh, Ling Ling ^e   Cheng, Shu Hui ^b   Chu, Ching Lin ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^d ELI LILLY AND COMPANY   (United States)

^e ASIA UNIVERSITY   (Taiwan)

Author keywords

Antipsychotics; Cost of illness; Drug side effects; Functionality; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; AGED; ARTICLE; CAREGIVER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; EXTRAPYRAMIDAL SYNDROME; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH CARE COST; HEALTH SERVICE; HEALTH SURVEY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT CARE; PRIORITY JOURNAL; SCHIZOPHRENIA; TAIWAN;

ADULT; AGE FACTORS; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; COST OF ILLNESS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; NATIONAL HEALTH PROGRAMS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TAIWAN;

EID: 40149103093     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2006.10.004     Document Type: Article

References (49)

1. Andreasen N.C. Assessment issues and the cost of schizophrenia. Schizophrenia Bulletin 17 3 (1991) 475-481
2. Andrews G., Hall W., Goldstein G., Lapsley H., Bartels R., and Silove D. The economic costs of schizophrenia. Implications for public policy. Archives of General Psychiatry 42 6 (1985) 537-543
3. Andrews G., Sanderson K., Corry J., Issakidis C., and Lapsley H. Cost-effectiveness of current and optimal treatment for schizophrenia. British Journal of Psychiatry 183 (2003) 427-435
4. Angermeyer M.C., Breier P., Dietrich S., Kenzine D., and Matschinger H. Public attitudes toward psychiatric treatment. An international comparison. Social Psychiatry and Psychiatric Epidemiology 40 11 (2005) 855-864
5. Basu A. Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues. Schizophrenia Research 71 2-3 (2004) 445-462
6. Breakey W.R. Developmental milestones for community psychiatry. In: Breakey W.R. (Ed). Integrated Mental Health Services (1996), Oxford University Press, New York 29-42
7. Bureau of National Health Insurance. Introduction of Bureau of National Health Insurance (2000), Bureau of National Health Insurance
8. Burns T., and Raftery J. Cost of schizophrenia in a randomized trial of home-based treatment. Schizophrenia Bulletin 17 3 (1991) 407-410
9. Carr V.J., Lewin T.J., Neil A.L., Halpin S.A., and Holmes S. Premorbid, psychosocial and clinical predictors of the costs of schizophrenia and other psychoses. British Journal of Psychiatry 184 (2004) 517-525
10. Chen P.S., Cheng S.H., Yang Y.K., Yel T.L., Cheng S.J., and Yang M.J. Help-seeking behaviors and disease perception in psychiatric patients and their families in a teaching hospital. Chinese Journal of Family Medicine 12 (2002) 32-42
11. Chien, I.-C.,2004. Prevalence, use, and costs of psychiatric disorders among National Health insurance enrollees in Taiwan [Ph.D.]. Taipei: National Yang-Ming University. 170 p.
12. Endicott J., Spitzer R.L., Fleiss J.L., and Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry 33 6 (1976) 766-771
13. Evers S.M., and Ament A.J. Costs of schizophrenia in the Netherlands. Schizophrenia Bulletin 21 1 (1995) 141-153
14. Gibson P.J., Damler R., Jackson E.A., Wilder T., and Ramsey J.L. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population. Value in Health 7 1 (2004) 22-35
15. Goeree R., O'Brien B.J., Goering P., Blackhouse G., Agro K., Rhodes A., and Watson J. The economic burden of schizophrenia in Canada. Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie 44 5 (1999) 464-472
16. Guest J.F., and Cookson R.F. Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis. PharmacoEconomics 15 6 (1999) 597-610
17. Gunderson J.G., and Mosher L.R. The cost of schizophrenia. American Journal of Psychiatry 132 9 (1975) 901-906
18. Hall W., Goldstein G., Andrews G., Lapsley H., Bartels R., and Silove D. Estimating the economic costs of schizophrenia. Schizophrenia Bulletin 11 4 (1985) 598-610
19. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13 2 (1987) 261-276
20. Knapp M. Schizophrenia costs and treatment cost-effectiveness. Acta Psychiatrica Scandinavica Supplementum 407 (2000) 15-18
21. Knapp M., Chisholm D., Leese M., Amaddeo F., Tansella M., Schene A., Thornicroft G., Vazquez-Barquero J.L., Knudsen H.C., Becker T., et al. Comparing patterns and costs of schizophrenia care in five European countries: the EPSILON study. European Psychiatric Services: Inputs Linked to Outcome Domains and Needs. Acta Psychiatrica Scandinavica 105 1 (2002) 42-54
22. Knapp M., Mangalore R., and Simon J. The global costs of schizophrenia. Schizophrenia Bulletin 30 2 (2004) 279-293
23. Ko S.Y., Chen P.S., Yang Y.K., Liao Y.C., Lee Y.D., and Yang M.J. The correlation between performance on the continuous performance test and economic costs in patients with schizophrenia. Psychiatry and Clinical Neurosciences 57 (2003) 373-377
24. Krauss M.W., and Erickson M. Informal support networks among aging persons with mental retardation: a pilot study. Mental Retardation 26 4 (1988) 197-201
25. Lin K.M., Inui T.S., Kleinman A.M., and Womack W.M. Sociocultural determinants of the help-seeking behavior of patients with mental illness. Journal of Nervous and Mental Disease 170 2 (1982) 78-85
26. Lin E.C., Yin T.J., Kuo B.I., Chang W.Y., and Tsai S.L. A comparison of effectiveness and cost between two models of care for individuals with schizophrenia living in Taiwan. Archives of Psychiatric Nursing 15 6 (2001) 272-278
27. Lish J.D., Dime-Meenan S., Whybrow P.C., Price R.A., and Hirschfeld R.M. The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. Journal of Affective Disorders 31 4 (1994) 281-294
28. Manca A., Rice N., Sculpher M.J., and Briggs A.H. Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Economics 14 5 (2005) 471-485
29. Muller C.F., and Caton C.L. Economic costs of schizophrenia: a postdischarge study. Medical Care 21 1 (1983) 92-104
30. Provencher H.L., Fournier J.P., Perreault M., and Vezina J. The caregiver's perception of behavioral disturbance in relatives with schizophrenia: a stress-coping approach. Community Mental Health Journal 36 3 (2000) 293-306
31. Rice D.P. The economic impact of schizophrenia. Journal of Clinical Psychiatry 60 Suppl 1 (1999) 4-6
32. Rice D.P., and Miller L.S. The economic burden of schizophrenia: conceptual and methodological issues, and cost estimates. In: Moscarelli M., Rupp A., and Sartorius N. (Eds). Handbook of Mental Health Economics and Health Policy (1996), John Wiley & Sons, West Sussex 321-334
33. Rouillon F., Toumi M., Dansette G.Y., Benyaya J., and Auquier P. Some aspects of the cost of schizophrenia in France. PharmacoEconomics 11 6 (1997) 578-594
34. Rudnick A., and Kravetz S. The relation of social support-seeking to quality of life in schizophrenia. Journal of Nervous and Mental Disease 189 4 (2001) 258-262
35. Rund B.R., and Ruud T. Costs of services for schizophrenic patients in Norway. Acta Psychiatrica Scandinavica 99 2 (1999) 120-125
36. Sevy S., Visweswaraiah H., Mentschel C., Leucht S., and Schooler N.R. Relationship between costs and symptoms in schizophrenia patients treated with antipsychotic medication: a review. Journal of Clinical Psychiatry 65 6 (2004) 756-765
37. Shibre T., Negash A., Kullgren G., Kebede D., Alem A., Fekadu A., Fekadu D., Madhin G., and Jacobsson L. Perception of stigma among family members of individuals with schizophrenia and major affective disorders in rural Ethiopia. Social Psychiatry and Psychiatric Epidemiology 36 6 (2001) 299-303
38. Simpson G.M., and Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica Supplementum 212 (1970) 11-19
39. Stueve A., Vine P., and Struening E.L. Perceived burden among caregivers of adults with serious mental illness: comparison of black, Hispanic, and white families. American Journal of Orthopsychiatry 67 2 (1997) 199-209
40. Taiwan Year Book, 2005. Government Information Office. http://www.gio.gov.tw.
41. Tarricone R., Gerzeli S., Montanelli R., Frattura L., Percudani M., and Racagni G. Direct and indirect costs of schizophrenia in community psychiatric services in Italy. The GISIES study. Interdisciplinary Study Group on the Economic Impact of Schizophrenia. Health Policy 51 1 (2000) 1-18
42. Thornicroft G., and Tansella M. The implications of epidemiology for service planning in schizophrenia. In: Murry R.M., Jones P.B., Susser E., Os J.V., and Cannon M. (Eds). The Epidemiology of Schizophrenia (2003), Cambridge University Press, United Kingdom 411-426
43. Velligan D.I., Bow-Thomas C.C., Mahurin R.K., Miller A.L., and Halgunseth L.C. Do specific neurocognitive deficits predict specific domains of community function in schizophrenia?. Journal of Nervous and Mental Disease 188 8 (2000) 518-524
44. Wasylenki D.A. The cost of schizophrenia. Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie 39 9 Suppl 2 (1994) S65-S69
45. Wu C.C., Yang Y.K., and Huang M.K. A brief method for assessing expressed emotion and the role of high expressed emotion in family caregiver burden and patient rejection. Bulletin of Health Education 9 (1996) 37-62 (Full text in Chinese)
46. Yang Y.K., Hsieh H.H., Wu A.C., Yeh T.L., and Chen C.C. Help-seeking behaviors in relatives of schizophrenics in Taiwan. General Hospital Psychiatry 21 4 (1999) 303-309
47. Yang Y.K., Tarn Y.H., Wang T.Y., Liu C.Y., Liao Y.C., Chou Y.H., Lee S.M., and Chen C.C. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. Psychiatry and Clinical Neurosciences 59 4 (2005) 385-394
48. Yeh L.L., Lee Y.L., and Yang M.C. The economic cost of severely mentally ill patients. Chinese Journal of Mental Health 10 (1997) 1-15
49. Yeh L.L., Lan C.F., and Cheng J.J. The utilization and expenditure of psychiatric services for patients with schizophrenia in Taiwan. Taiwan Journal of Public Health 22 (2003) 194-203